263 results on '"Shahinfar, Shahnaz"'
Search Results
2. An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis
3. Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis
4. Losartan and enalapril are comparable in reducing proteinuria in children
5. Relative Incidence of ESRD Versus Cardiovascular Mortality in Proteinuric Type 2 Diabetes and Nephropathy: Results From the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) Database
6. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
7. Renal Disease in Minority Populations and Developing Nations
8. Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome
9. A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension
10. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study
11. The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy
12. Creatinine Excretion Rate and Mortality in Type 2 Diabetes and Nephropathy
13. A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertension
14. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
15. Efficacy and safety of losartan in children with Alport syndrome—results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial
16. International consensus definitions of clinical trial outcomes for kidney failure: 2020
17. A double-blind, dose-response study of losartan in hypertensive children
18. Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: New lessons from the RENAAL Study
19. Hospitalizations for New Heart Failure Among Subjects With Diabetes Mellitus in the RENAAL and LIFE Studies
20. Effect of LDL Cholesterol and Treatment With Losartan on End-Stage Renal Disease in the RENAAL Study
21. Efficacy and Safety of Angiotensin II Receptor Blockade in Elderly Patients With Diabetes
22. Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy
23. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy
24. Importance of Baseline Distribution of Proteinuria in Renal Outcomes Trials: Lessons from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study
25. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL
26. Continuum of Renoprotection with Losartan at All Stages of Type 2 Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL Trial Results
27. Detecting and managing patients with type 2 diabetic kidney disease: Proteinuria and cardiovascular disease
28. The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy
29. Renin Angiotensin Aldosterone System Blockade and Renal Disease in Patients With Type 2 Diabetes: An Asian perspective from the RENAAL study
30. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis
31. Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis
32. LOSARTAN TREATMENT EFFECT ON RENAL OUTCOMES IN TYPE 2 DIABETIC PATIENTS WITH NEPHROPATHY AFTER ADJUSTING FOR AN IMBALANCE IN BASELINE PROTEINURIA
33. Pharmacokinetics, Safety, and Antihypertensive Efficacy of Losartan in Combination with Hydrochlorothiazide in Hypertensive Patients with Renal Impairment
34. Analysis of Metabolic Parameters as Predictors of Risk in the RENAAL Study
35. Dialysis delayed is death prevented: A clinical perspective on the RENAAL study
36. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study
37. Losartan Reduces the Costs Associated With Diabetic End-Stage Renal Disease: The RENAAL study economic evaluation
38. A Double-Blind, Placebo-Controlled, Dose-Response Study of the Effectiveness and Safety of Enalapril for Children with Hypertension
39. Treatment of type 2 diabetic patients with kidney disease with AT1-receptor antagonists: lessons from recent trials
40. The Pharmacokinetics of Enalapril in Children and Infants with Hypertension
41. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease
42. Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease: A Meta-Analysis of Patient-Level Data
43. A double-blind, placebo-controlled, dose–response study of the effectiveness and safety of lisinopril for children with hypertension
44. Trends in Persistent Proteinuria in Adult-Onset Diabetes: A population-based study
45. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia
46. Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European Union
47. Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study
48. Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis
49. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis
50. An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.